Cholesterol Crystal Embolism and Chronic Kidney Disease.
Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease.
Cholesterol Crystal Embolism: Autopsy-proven Gastrointestinal Lesions, Pancreatitis, and End-stage Kidney Disease Which Developed after Undergoing Selective Abdominal Angiography.
Cholesterol Crystal Embolism and Chronic Kidney Disease.
Li X, Bayliss G, Zhuang S.
Int J Mol Sci. 2017 May 24;18(6):1120. doi: 10.3390/ijms18061120.
Cholesterol crystal embolism: A recognizable cause of renal disease.
Scolari F, Tardanico R, Zani R, Pola A, Viola BF, Movilli E, Maiorca R.
Am J Kidney Dis. 2000 Dec;36(6):1089-109. doi: 10.1053/ajkd.2000.19809.
Cholesterol crystal embolization induced kidney disease.
Pervaze S, Mohandas S, Gopalan P, Morse SA, Bajracharya S, Krone LA, Yazdi F.
Am Heart J Plus. 2025 Jul 2;56:100572. doi: 10.1016/j.ahjo.2025.100572. eCollection 2025 Aug.
[Update on cholesterol crystal embolism].
Denis Le Seve J, Gourraud Vercel C, Connault J, Artifoni M.
Rev Med Interne. 2020 Apr;41(4):250-257. doi: 10.1016/j.revmed.2020.02.002. Epub 2020 Feb 19.
Atheroembolic Kidney Disease.
Rout P, Hashmi MF, Finnigan NA.
2024 Jun 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Inhibition of complement factor C5a or C5aR for cholesterol crystal embolism-related vascular thrombosis with microvascular injury and its consequences.
Zhao D, Han C, Mammadova-Bach E, Watanabe-Kusunoki K, Bandeira Honda TS, Li Y, Li C, Li Q, Long H, Lyubenov L, Shi C, Santovito D, Weber C, Boor P, Droste P, Parikh S, Shapiro J, De Chiara L, Carangelo G, Romagnani P, Klussmann S, Hoehlig K, Vater A, Anders HJ.
Kidney Int. 2024 Nov;106(5):819-825. doi: 10.1016/j.kint.2024.07.020. Epub 2024 Aug 12.
Cholesterol Crystal Embolism: Autopsy-proven Gastrointestinal Lesions, Pancreatitis, and End-stage Kidney Disease Which Developed after Undergoing Selective Abdominal Angiography.
Yamamoto N, Sakai N, Kaikoi D, Yomogida D, Kajikawa S, Wada T, Yuasa T, Ogura H, Sato K, Miyagawa T, Kitajima S, Toyama T, Hara A, Shimizu M, Wada T, Iwata Y.
Intern Med. 2024 Dec 15;63(24):3325-3331. doi: 10.2169/internalmedicine.3469-24. Epub 2024 May 9.
Crystal Clots as Therapeutic Target in Cholesterol Crystal Embolism.
Shi C, Kim T, Steiger S, Mulay SR, Klinkhammer BM, Bäuerle T, Melica ME, Romagnani P, Möckel D, Baues M, Yang L, Brouns SLN, Heemskerk JWM, Braun A, Lammers T, Boor P, Anders HJ.
Circ Res. 2020 Apr 10;126(8):e37-e52. doi: 10.1161/CIRCRESAHA.119.315625. Epub 2020 Feb 24.
Intravenous Glu-plasminogen attenuates cholesterol crystal embolism-induced thrombotic angiopathy, acute kidney injury and kidney infarction.
Lyubenov L, Shi C, Zhao D, Yang L, Lei Y, Mammadova-Bach E, de Chiara L, Semeraro R, Landini S, Romagnani P, Vörg E, Devarapu SK, Welz R, Kiessig ST, Anders HJ.
Nephrol Dial Transplant. 2023 Jan 23;38(1):93-105. doi: 10.1093/ndt/gfac273.
Cholesterol crystal embolization.
Morales JM, Gonzalez E.
Blood Purif. 2006;24(5-6):431-2. doi: 10.1159/000095358. Epub 2006 Aug 25.
